PROKIDNEY CORP. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.015 USD | +2.42% |
|
+50.19% | +120.22% |
| May. 10 | ProKidney Q1 Loss Unchanged From Year Earlier | MT |
| May. 10 | ProKidney Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 242M |
|---|---|---|---|---|---|
| Net income 2024 * | -146M | Net income 2025 * | -43M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 178M | Net cash position 2025 * | 310M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.85
x | P/E ratio 2025 * |
-4.97
x | Employees | 163 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.55% |
More Fundamentals
* Assessed data
More news
Latest transcript on ProKidney Corp.
More recommendations
More press releases
| 1 day | -4.85% | ||
| 1 week | +50.19% | ||
| Current month | +89.83% | ||
| 1 month | +44.12% | ||
| 3 months | +149.68% | ||
| 6 months | +218.70% | ||
| Current year | +120.22% |
1 week
2.87
4.33
1 month
1.954.33
Current year
1.184.33
1 year
1.1213.51
3 years
1.1214.19
5 years
1.1214.19
10 years
1.1214.19
| Managers | Title | Age | Since |
|---|---|---|---|
Bruce Culleton
CEO | Chief Executive Officer | 57 | 23-07-16 |
James Coulston
DFI | Director of Finance/CFO | 48 | 21-12-31 |
Joseph Stavas
CTO | Chief Tech/Sci/R&D Officer | 69 | 19-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bill Doyle
BRD | Director/Board Member | 61 | 21-12-31 |
Brian Pereira
BRD | Director/Board Member | 65 | 21-12-31 |
John Maraganore
BRD | Director/Board Member | 60 | 22-08-10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +4.26% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 3.92 | -4.85% | 1 434 217 |
| 24-05-16 | 3.79 | -3.32% | 412,741 |
| 24-05-15 | 3.92 | -4.85% | 1,434,217 |
| 24-05-14 | 4.12 | +33.77% | 2,703,484 |
| 24-05-13 | 3.08 | +9.61% | 488,210 |
End-of-day quote Nasdaq, May 14, 2024
More quotes
ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patientâs own cells isolated from the patient intended for treatment. The Companyâs lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patientâs diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patientâs own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participantâs own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).
Calendar
2024-05-25
- ERA Congress
Related indices
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
3.79
USD
Average target price
4.4
USD
Spread / Average Target
+16.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +120.22% | 242M | |
| +33.37% | 50.85B | |
| +1.55% | 42.82B | |
| +49.28% | 42.03B | |
| -4.22% | 29.55B | |
| +11.57% | 26.11B | |
| -21.00% | 19.13B | |
| +7.36% | 13.05B | |
| +28.30% | 12.16B | |
| +23.80% | 12.08B |
- Stock Market
- Equities
- PROK Stock